#AVBP

2 weeks ago

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! Weekly Top Unu

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

Weekly Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #FIGR 223% OTM
2. #ROOT 90% OTM
3. #AVBP 47% OTM
4. #FLNC 46% OTM
5. #RUN 41% OTM

#OptionFlow #OptionsTrading #Trading

0 0 0 0

2 weeks ago

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#ROOT, #ZETA, #AVBP, #AAL, #EOSE

#OptionFlow #OptionsTrading #Trading

0 1 0 0

2 weeks ago

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! PM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #ROOT 90% OTM
2. #ZETA 49% OTM
3. #AVBP 47% OTM
4. #IREN 45% OTM
5. #AAL 39% OTM

#OptionFlow #OptionsTrading #Trading

0 1 0 0

2 weeks ago

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#AVBP, #IREN, #CVNA, #EOSE, #AMPX

#OptionFlow #OptionsTrading #Trading

0 0 0 0

2 weeks ago

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! AM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

AM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #IREN 47% OTM
2. #AVBP 47% OTM
3. #EOSE 34% OTM
4. #CVNA 33% OTM
5. #AMPX 30% OTM

#OptionFlow #OptionsTrading #Trading

2 1 0 0

1 month ago

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#BE, #IREN, #AVBP, #CVNA, #MU

#OptionFlow #OptionsTrading #Trading

0 0 0 0

@smcapstrategist.bsky.social

1 month ago

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! AM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

AM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #SNDK 34% OTM
2. #BE 33% OTM
3. #IREN 22% OTM
4. #AVBP 16% OTM
5. #KD 15% OTM

#OptionFlow #OptionsTrading #Trading

0 0 0 0

Small Cap Strategist

2 months ago

Leading Indicators, Monday January 5, 2026 – Crystal Equity Research

Small-cap stocks in new downtrend according to average directional index, Mon Jan 5th - #INFU #LUCY #TOUR #ORKA #FLGT #DGNX #AVBP #TK #LB #CXM #CATO #AMPY - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

PRISM MarketView

@prismmarketview.bsky.social

2 months ago

Hands gently cupping a translucent lung icon, symbolizing lung cancer research and advanced respiratory therapeutics.

ArriVent BioPharma (Nasdaq: #AVBP) has dosed the first patient in its global Phase 3 ALPACCA trial evaluating firmonertinib as a first-line, chemo-free treatment for EGFR PACC mutant NSCLC—an underserved population with limited targeted options.
prismmarketview.com/arrivent-dos...

0 0 0 0

4 months ago

#AVBP ArriVent BioPharma Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/AVBP/arri-vent-bio-...

0 0 0 0

ArriVent BioPharma Reports Second Quarter 2025 Financial Results ArriVent BioPharma (NASDAQ:AVBP) reported Q2 2025 financial results and pipeline updates. The company highlighted positive interim Phase 1b data for firmonertinib in EGFR PACC mutant NSCLC, with plans to initiate the global Phase 3 ALPACCA study in 2H 2025. The company also dosed the first patient in a Phase 1 study of ARR-217, their CDH17-targeted ADC for gastrointestinal tumors.Financially, ArriVent reported $254.5 million in cash and investments as of June 30, 2025, plus an additional $81.1 million raised in July 2025, extending their runway to mid-2027. The company's net loss increased to $95.8 million for H1 2025, compared to $39.3 million in H1 2024, primarily due to a $40 million upfront payment to Lepu Biopharma.

7 months ago

#AVBP ArriVent BioPharma Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/AVBP/arri-vent-bio-...

0 0 0 0

AVBP - Arrivent Biopharma Inc Latest Stock News & Market Updates ArriVent BioPharma (AVBP) news hub: Track clinical trials, FDA milestones & oncology innovations. Your source for EGFR inhibitor developments & biopharma updates.

7 months ago

#AVBP ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026

www.stocktitan.net/news/AVBP/arri-vent-s-to...

0 0 0 0

ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants ArriVent BioPharma (Nasdaq: AVBP) has announced the pricing of a public offering expected to raise approximately $75 million in gross proceeds. The offering consists of 2,482,692 shares of common stock priced at $19.50 per share and pre-funded warrants to purchase up to 1,363,469 shares at $19.4999 per warrant.The company has granted underwriters a 30-day option to purchase up to an additional 576,923 shares. The offering, led by Goldman Sachs, Citigroup, and Guggenheim Securities as joint book-running managers, is expected to close around July 3, 2025.ArriVent plans to use the net proceeds to support activities for firmonertinib and other pipeline programs, along with working capital and general corporate purposes. The offering is being made pursuant to an automatic shelf registration statement filed with the SEC.

8 months ago

#AVBP ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

www.stocktitan.net/news/AVBP/arri-vent-anno...

0 0 0 0

Biotech ArriVent BioPharma Seeks $75M in Fresh Capital to Advance Cancer Drug Pipeline Clinical-stage biotech secures Goldman Sachs, Citigroup as underwriters for new offering. Proceeds to fuel firmonertinib development. Get full details.

8 months ago

#AVBP ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants

www.stocktitan.net/news/AVBP/arri-vent-anno...

0 0 0 0

ArriVent to Unveil Next Steps for Breakthrough EGFR PACC Lung Cancer Drug Firmonertinib Key updates on firmonertinib's development for rare EGFR PACC mutant lung cancer to be revealed. Join virtual investor event for exclusive program insights.

8 months ago

#AVBP ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC

www.stocktitan.net/news/AVBP/arri-vent-anno...

0 0 0 0

ArriVent BioPharma Reports First Quarter 2025 Financial Results ArriVent BioPharma (AVBP) reported its Q1 2025 financial results with significant pipeline progress. The company completed enrollment in its global pivotal Phase 3 FURVENT study for firmonertinib in first-line NSCLC with EGFR exon 20 insertion mutations. ArriVent expanded its pipeline by acquiring ARR-217, a CDH17-targeted ADC for gastrointestinal cancers, through a collaboration with Lepu Biopharma. The company's financial position shows $205.5 million in cash and equivalents, expected to fund operations into H2 2026. Q1 2025 resulted in a net loss of $64.4 million, compared to $17.4 million in Q1 2024, primarily due to a $40 million upfront payment to Lepu Biopharma. R&D expenses increased to $61.3 million, while G&A expenses rose to $5.5 million.

10 months ago

#AVBP ArriVent BioPharma Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/AVBP/arri-vent-bio-...

0 0 0 0

ArriVent BioPharma Reports Full Year 2024 Financial Results ArriVent BioPharma (Nasdaq: AVBP) reported its full year 2024 financial results and key milestones. The company achieved target enrollment of 375 patients in its global Phase 3 study of firmonertinib for first-line NSCLC with EGFR exon 20 insertion mutations. Clinical data showed robust responses for firmonertinib in first-line NSCLC EGFR PACC mutations.Financial highlights include cash and equivalents of $266.5 million as of December 31, 2024, expected to fund operations into 2026. The company reported a net loss of $80.5 million for 2024, compared to $69.3 million in 2023. R&D expenses increased to $79.0 million from $64.9 million in 2023.Pipeline developments include selecting ADC candidate ARR-002 for IND enabling studies, adding ARR-217 through Lepu Biopharma collaboration, and entering an ADC partnership with Alphamab. The company expects to provide updates on firmonertinib PACC development plans and Phase 3 top-line data timing in 2025.

1 year ago

#AVBP ArriVent BioPharma Reports Full Year 2024 Financial Results

www.stocktitan.net/news/AVBP/arri-vent-bio-...

0 0 0 0

ArriVent BioPharma Secures Global Rights to Promising Cancer Drug MRG007 in $1.2B Deal ArriVent acquires exclusive rights to novel ADC targeting GI cancers in $47M upfront deal with Lepu Biopharma. IND submission planned for 2025, potential $1.16B in milestones.

1 year ago

#AVBP ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers

www.stocktitan.net/news/AVBP/arri-vent-bio-...

0 0 0 0